Their contributions covered key topics such as cell therapies, hematopoietic transplantation, and the identification of new biomarkers for hematologic diseases.
Contributions in advanced therapies and transplantation
The Hematology Department at Hospital Clínic Barcelona and several IDIBAPS research groups presented more than ten communications, including posters, abstracts, and one oral presentation.
These studies addressed strategic research areas such as:
-
CAR-T advanced therapies for multiple myeloma, incorporating real-world data and multi-omic analysis.
-
Hematopoietic transplantation, with studies on prognostic factors and the impact of donor age.
-
Novel biomarkers and predictive models in lymphomas and myelodysplastic syndromes.
-
Translational research aimed at improving patient survival and quality of life.
Among the oral communications, Aina Oliver-Caldés presented real-world results from the CAR-T therapy cesni-cel (ARI0002h) study.
The research included patients with refractory multiple myeloma, with a median age of 62 years and three prior lines of therapy.
Preliminary results showed an overall response rate of 95% and a median progression-free survival of 19 months, with a favorable safety profile due to the fractionated administration of the therapy.
Most of the communications presented at the congress received the ASH Abstract Achievement Award, highlighting their scientific excellence and impact.
These contributions demonstrate the Clínic Barcelona Comprehensive Cancer Centre’s (4CB) steadfast commitment to innovation, high-quality research, and the transfer of knowledge into clinical care.
International mentoring and training excellence
In addition to the scientific presentations, Dr. Iñaki Martin-Subero participated as director of the Translational Research Training in Hematology (TRTH) program, co-organized by ASH and EHA, which held a dedicated session in Orlando.
This initiative reinforces Hospital Clínic-IDIBAPS’ role in training the next generation of hematology researchers.
A global leader in research and care
The 4CB’s participation at ASH 2025 reaffirmed its international leadership in hematology, with a strong commitment to advanced therapies, personalized medicine, and global collaboration to improve patient outcomes and quality of life.
